This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.
Germing U, Kundgen A, Gattermann N . Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004; 45: 1311–1318.
Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, van Biezen A et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 67–73.
Kerbauy DM, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005; 11: 713–720.
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q− deletion. N Engl J Med 2006; 355: 1456–1465.
Lancet JE, List AF, Moscinski LC . Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 2007; 21: 586–588.
Giagounidis AA, Germing U, Aul C . Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006; 12: 5–10.
Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L et al. Narrowing and genomic annotation of the commonly deleted region of the 5q− syndrome. Blood 2002; 99: 4638–4641.
Acknowledgements
We thank all technicians for excellent assistance in performing cytogenetic studies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Platzbecker, U., Mohr, B., von Bonin, M. et al. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 21, 2384–2385 (2007). https://doi.org/10.1038/sj.leu.2404811
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404811
This article is cited by
-
Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia—a wise Liaison?
Leukemia (2013)
-
Outcome of allo-SCT for chronic myelomonocytic leukemia
Bone Marrow Transplantation (2009)
-
Diagnosis and management of chronic myelomonocytic leukemia
Current Hematologic Malignancy Reports (2008)